• Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016
Monday Morning
Skip to content
  • Home
  • About
  • Contact
  • Steve Walker
  • Subscriptions
    • Sample MondayMorning Newsletter January 11, 2016

Tag Archives: Larotrectinib

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve Walker    June 12, 2017 May 7, 2018    No Comments on ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Disease, Pharmaceuticals    Adam Feuerstein, American Society of Clinical Oncology, Bluebird Bio Inc., Brad Loncar, Celgene Corp., Celldex Inc., Dynavax Technologies Inc., EP Vantage, Fortune, Glemba, Herceptin, Incyte Corp., Keytruda, Larotrectinib, Laurie McGinley, Loxo Oncology Inc., Merck & Co., Michael S. Sabel, Nanjing Legend Biotech, Nick Leschly, Opdivo, Perjeta, Roche Holding AG, TheStreet.com, Washington Post

Search The Site

Follow @MonMorningNews

Twitter

Tweets by MonMorningNews
Follow me on Blogarama

Facebook

Search The Site

More MondayMorning

  • Recent Posts
  • Most Commented
  • Most Viewed
  • US stock market has a subdued Thanksgiving week, but a slew of healthcare companies rocketed higher.
  • More Chinese medical companies choosing New York over Shanghai, Hong Kong for IPOs; but not always.
  • Health-sector IPO market cools off for Veterans Day breather; but pre-Thanksgiving deals ready to rock.
  • Health-sector IPO market cools off this week after torrid start to November.
    • Insys trial opens with tale of sales rep giving lap dance to doctor for fentanyl prescriptions. News organizations seize upon...
    • Voyager Therapeutics signs another neurodegenerative disease deal with AbbVie that screams “Buy this small cap now.”
    • Little known Czech biotech’s cell therapy greatly increases survival in ovarian cancer. Sotio’s potential breakthrough and another pipeline cancer candidate...
    • It’s time to reclassify schizophrenia as a neurologic disorder.
    Copyright 2018
    Ribosome by GalussoThemes.com
    Powered by WordPress